Q32 Bio Statistics
Total Valuation
Q32 Bio has a market cap or net worth of $276.80 million. The enterprise value is -$7.67 million.
| Market Cap | 276.80M |
| Enterprise Value | -7.67M |
Important Dates
The last earnings date was Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Q32 Bio has 29.92 million shares outstanding. The number of shares has increased by 66.60% in one year.
| Current Share Class | 29.92M |
| Shares Outstanding | 29.92M |
| Shares Change (YoY) | +66.60% |
| Shares Change (QoQ) | +67.25% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 36.73% |
| Float | 13.51M |
Valuation Ratios
The trailing PE ratio is 5.83.
| PE Ratio | 5.83 |
| Forward PE | n/a |
| PS Ratio | 5.15 |
| Forward PS | 830.40 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 56.34, with a Debt / Equity ratio of 0.02.
| Current Ratio | 56.34 |
| Quick Ratio | 56.15 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.25 |
| Debt / FCF | n/a |
| Interest Coverage | 30.63 |
Financial Efficiency
Return on equity (ROE) is 23.96% and return on invested capital (ROIC) is 7.88%.
| Return on Equity (ROE) | 23.96% |
| Return on Assets (ROA) | 6.47% |
| Return on Invested Capital (ROIC) | 7.88% |
| Return on Capital Employed (ROCE) | 6.29% |
| Weighted Average Cost of Capital (WACC) | 3.74% |
| Revenue Per Employee | $2.15M |
| Profits Per Employee | $1.29M |
| Employee Count | 25 |
| Asset Turnover | 0.30 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +287.03% in the last 52 weeks. The beta is -0.11, so Q32 Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +287.03% |
| 50-Day Moving Average | 9.72 |
| 200-Day Moving Average | 9.36 |
| Relative Strength Index (RSI) | 53.67 |
| Average Volume (20 Days) | 474,886 |
Short Selling Information
The latest short interest is 5.65 million, so 18.89% of the outstanding shares have been sold short.
| Short Interest | 5.65M |
| Short Previous Month | 4.67M |
| Short % of Shares Out | 18.89% |
| Short % of Float | 41.84% |
| Short Ratio (days to cover) | 5.24 |
Income Statement
In the last 12 months, Q32 Bio had revenue of $53.74 million and earned $32.25 million in profits. Earnings per share was $1.59.
| Revenue | 53.74M |
| Gross Profit | 37.80M |
| Operating Income | 18.38M |
| Pretax Income | 32.25M |
| Net Income | 32.25M |
| EBITDA | 18.73M |
| EBIT | 18.38M |
| Earnings Per Share (EPS) | $1.59 |
Balance Sheet
The company has $289.59 million in cash and $5.12 million in debt, with a net cash position of $284.47 million or $9.51 per share.
| Cash & Cash Equivalents | 289.59M |
| Total Debt | 5.12M |
| Net Cash | 284.47M |
| Net Cash Per Share | $9.51 |
| Equity (Book Value) | 287.67M |
| Book Value Per Share | 9.62 |
| Working Capital | 285.96M |
Cash Flow
In the last 12 months, operating cash flow was -$20.02 million and capital expenditures -$52,000, giving a free cash flow of -$20.07 million.
| Operating Cash Flow | -20.02M |
| Capital Expenditures | -52,000 |
| Depreciation & Amortization | 349,000 |
| Net Borrowing | -11.38M |
| Free Cash Flow | -20.07M |
| FCF Per Share | -$0.67 |
Margins
Gross margin is 70.34%, with operating and profit margins of 34.20% and 60.02%.
| Gross Margin | 70.34% |
| Operating Margin | 34.20% |
| Pretax Margin | 60.02% |
| Profit Margin | 60.02% |
| EBITDA Margin | 34.85% |
| EBIT Margin | 34.20% |
| FCF Margin | n/a |
Dividends & Yields
Q32 Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -66.60% |
| Shareholder Yield | -66.60% |
| Earnings Yield | 17.14% |
| FCF Yield | -7.25% |
Analyst Forecast
The average price target for Q32 Bio is $39.67, which is 328.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.67 |
| Price Target Difference | 328.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -68.58% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Q32 Bio has an Altman Z-Score of 10.34 and a Piotroski F-Score of 3.
| Altman Z-Score | 10.34 |
| Piotroski F-Score | 3 |